Drug profile · INN
dofetilide
TIKOSYN
dofetilide (TIKOSYN) is a herg blocker. Associated with Teva Pharma GmbH. Route of administration: oral. Current US regulatory status: approved.
Drug details — dofetilide
- US status
- approved
- Class
- Cardiovascular system (C01)
- Route
- ORAL
- Patents
- 1
- Programs
- 1
- Data quality
- 0.89
Quick answer
dofetilide (TIKOSYN) is a herg blocker. Associated with Teva Pharma GmbH. Route of administration: oral. Current US regulatory status: approved.
Key facts
Mechanism of action
HERG blocker
Primary target: Voltage-gated inwardly rectifying potassium channel KCNH2
Approval history
| Authority | Status | Date |
|---|---|---|
| FDA | approved | — |
| EMA | withdrawn | — |
Pipeline programs
Related & competitor drugs
Related patents
Frequently asked questions
What is dofetilide?
dofetilide (TIKOSYN) is a herg blocker. Associated with Teva Pharma GmbH. Route of administration: oral. Current US regulatory status: approved.
What is the brand name for dofetilide?
TIKOSYN is a marketed brand name for dofetilide. Check FDA Drugs@FDA for the current US label holder and prescribing information.
What is the US approval status of dofetilide?
dofetilide has approved status in the United States according to our Drugs@FDA-derived records. Verify on the official FDA label before clinical or commercial decisions.